Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of Aβ42 in patients with Alzheimer's disease

Amyloid

Volumn 10, Issue 1, 2003, Pages 1-6

  Hock, Christoph ^a   Maddalena, Alessia ^a   Raschig, Andreas ^b   Müller Spahn, Franz ^c   Eschweiler, Gerhard ^d   Hager, Klaus ^e   Heuser, Isabella ^f   Hampel, Harald ^g   Müller Thomsen, Thomas ^h   Oertel, Wolfgang ⁱ   Wienrich, Marion ^b   Signorell, Andri ^a   Gonzalez Agosti, Charo ^a   Nitsch, Roger M ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c UNIVERSITY OF BASEL   (Switzerland)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e Clinic for Medical Rehabilitation and Geriatrics   (Germany)

^f FREIE UNIVERSITÄT BERLIN   (Germany)

^g UNIVERSITY OF MUNICH   (Germany)

^h UNIVERSITY OF HAMBURG   (Germany)

ⁱ PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Alpha secretase; Alzheirner's disease; Amyloid; A PP; Cholinergic

Indexed keywords

ALPHA SECRETASE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; GAMMA SECRETASE; MUSCARINIC M1 RECEPTOR AGONIST; PLACEBO; PROTEINASE; TALSACLIDINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; DRUG SELECTIVITY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROCESSING; RANDOMIZED CONTROLLED TRIAL; SENILE PLAQUE;

EID: 12444313989     PISSN: 13506129     EISSN: None     Source Type: Journal    
DOI: 10.3109/13506120308995249     Document Type: Article

References (27)

1. Shoji M, Golde TE, Ghiso J, Cheung TT, Estus S, Shaffer LM, Cai XD, McKay DM, Tintner R, Frangione B and Younkin SG (1992). Production of the Alzheimer amyloid β-protein by normal proteolytic processing. Science 258:126-129
2. Price DL, Tanzi RE, Borchelt DR and Sisodia SS (1998). Alzheimer's disease: genetic studies and transgenic models. Annu Rev Genet 32:461-493
3. Götz J, Chen F, van Dorpe J and Nitsch RM (2001). Formation of neurofibrillary tangles in P3011 tau transgenic mice induced by Abeta 42 fibrils. Science 293:1491-1495
4. Alonzo NC, Hyman BT, Rebeck GW and Greenberg SM (1998). Progression of cerebral amyloid angiopathy: accumulation of amyloid β-40 in affected vessels. J Neuropath Exp Neurol 57:353-359
5. Buxbaum JD, Gandy SE, Cicchetti P, Ehrlich ME, Czernik AJ, Fracasso RP, Ramabhadran TV, Unterbeck AJ and Greengard P (1990). Processing of Alzheimer beta/A4 amyloid precursor protein: modulation by agents that regulate protein phosphorylation. Proc Natl Acad Sci USA 87:6003-6006
6. Nitsch RM, Slack BE, Wurtman RJ and Growdon JH (1992). Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 258:304-310
7. Buxbaum JD, Koo EH and Greengard P (1993). Protein phosphorylation inhibits production of Alzheimer amyloid beta/A4 peptide. Proc Natl Acad Sci USA 90:9195-9198
8. Nitsch RM and Growdon JH (1994). Role of neurotransmission in the regulation of amyloid β-protein precursor processing. Biochem Pharmacol 47:275-284
9. Farber SA, Nitsch RM, Schultz JG and Wurtman RJ (1995). Regulated secretion of the β-amyloid precursor protein in rat brain. J Neurosci 15:7442-7450
10. Hung AY, Haass C, Nitsch RM, Qiu WQ, Citron M, Wurtman RJ, Growdon JH and Selkoe DJ (1993). Activation of protein kinase C inhibits cellular production of the amyloid beta-protein. J Biol Chem 268:.22959-22962
11. Nitsch RM, Deng M, Tennis M, Schoenfeld D and Growdon JH (2000). The selective muscarinic agonist AF102B decreases levels of total Aβ in CSF of patients with Alzheimer's disease. Ann Neurol 48:913-918
12. Ensinger HA, Doods HN, Immel-Sehr AR, Kuhn FJ, Lambrecht G, Mendla KD, Muller RE, Mutschler E, Sagrada A, Walther G and Hammer R (1993). WAL 2014 - a muscarinic agonist with preferential neuron-stimulating properties. Life Sci 52:473-480
13. Walland A, Burkard S, Hammer R and Troeger W (1997). In vivo consequences of ml-receptor activation by talsaclidine. Life Sci 60:977-984
14. Mueller DM, Mendla K, Farber SA and Nitsch RM (1997). Muscarinic ml receptor agonists increase the secretion of the amyloid precursor protein ectodomain. Life Sci 60:985-991
15. McKhann G, Drachman D, Folstein M, Katzmann R, Price D and Stadlan EM (1984). Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34:939-944
16. Word Health Organization: The 1CD10 Classification of Mental and Behavioral Disorders. Clinical Descriptions and Diagnostic Guidelines. WHO, Geneva 1992
17. Folstein MF, Folstein SE and McHugh PR (1975). Mini Mental State. A practical method for grading the cognitive state of patients for the clinician. J Psychiatry Res 12:189-198
18. Adamus WS, Leonard JP and Troeger W (1995). Phase I clinical trials with WAL 2014, a new muscarinic agonist for the treatment of Alzheimer's disease. Life Sci 56:883-890
19. Dobeli H, Draeger N, Huber G, Jakob P, Schmidt D, Seilheimer B, Stuber D, Wipf B and Zulauf M (1995). A biotechnological method provides access to aggregationcompetent monomeric Alzheimer's 1-42 residue amyloid peptide. Biotechnology 13:988-993
20. Kim KS, Miller DL, Sapienza VJ, Chen CMJ, Bai C, Grundke-Iqbal I, Currie JR and Wisniewski HM (1988). Production and characterisation of monoclonal antibodies reactive to synthetic cerebrovascular amyloid peptide. Neurosci Res Comm 2:121-130
21. Kim KS, Wen GY, Bancher C, Chen CMJ, Sapienza VJ, Hong H and Wisniewski HM (1990). Detection and quantitation of amyloid β-peptide with 2 monoclonal antibodies. Neurosci Res Commun 7:113-122
22. Brockhaus M, Grunberg J, Rohrig S, Loetscher H, Wittenburg N, Baumeister R, Jacobsen H and Haass C (1998). Caspase-mediated cleavage is not required for the activity of presenilins in amyloidogenesis and NOTCH signaling. Neuroreport 9:1481-1486
23. Rochet JC and Lansbury PT Jr (2000). Amyloid fibrillogenesis: themes and variations. Curr Opin Struct Biol 10:60-68
24. Walter J, Grunberg J, Capell A, Pesold B, Schindzielorz A, Citron M, Mendla K, George-Hyslop PS, Multhaup G, Selkoe DJ and Haass C (1997). Proteolytic processing of the Alzheimer diease-associated presenilin-1 generates an in vivo substrate for protein kinase C. Proc Natl Acad Sci USA 94:5349-5354
25. Wolfe MS, De Los Angeles J, Miller DD, Xia W and Selkoe DJ (1999). Are presenilins intramembrane-cleaving proteases? Implications for the molecular mechanism of Alzheimer's disease. Biochemistry 38:11223-11230
26. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, Larson E, Levy-Lahad E, Viitanen M, Peskind E, Poorkaj P, Schellenberg G, Tanzi R, Wasco W, Lannfelt L, Selkoe D and Younkin S (1996). Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 2:864-870
27. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D and Seubert P (1999). Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400:173-177